Enrolled
Underlined text would be added to current law. Struck-through text would be removed.
| S.B. No. 2308 |
| AN ACT | ||
| relating to the establishment of a consortium to conduct United | ||
| States Food and Drug Administration's drug development clinical | ||
| trials with ibogaine to secure the administration's approval of the | ||
| medication's use for treatment of opioid use disorder, co-occurring | ||
| substance use disorder, and any other neurological or mental health | ||
| conditions for which ibogaine demonstrates efficacy and to the | ||
| administration of that treatment. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Subtitle C, Title 6, Health and Safety Code, is | ||
| amended by adding Chapter 491 to read as follows: | ||
| CHAPTER 491. IBOGAINE TREATMENT | ||
| SUBCHAPTER A. GENERAL PROVISIONS | ||
| Sec. 491.001. DEFINITIONS. In this chapter: | ||
| (1) "Commission" means the Health and Human Services | ||
| Commission. | ||
| (2) "Comptroller" means the comptroller of public | ||
| accounts. | ||
| (3) "Drug developer" means a pharmaceutical company, | ||
| biotechnology company, or contract development and manufacturing | ||
| organization engaged in drug development and manufacturing. | ||
| (4) "Hospital" has the meaning assigned by Section | ||
| 241.003. | ||
| (5) "Ibogaine" means ibogaine and ibogaine-based | ||
| therapeutics, including ibogaine analogs. | ||
| (6) "Institution of higher education" has the meaning | ||
| assigned by Section 61.003, Education Code. | ||
| SUBCHAPTER B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT | ||
| Sec. 491.051. ESTABLISHMENT OF CONSORTIUM. (a) A | ||
| consortium may be established under this section and apply for | ||
| commission selection under this subchapter to conduct drug | ||
| development clinical trials with ibogaine and secure the United | ||
| States Food and Drug Administration's approval of ibogaine as a | ||
| medication for the treatment of: | ||
| (1) opioid use disorder; | ||
| (2) co-occurring substance use disorder; and | ||
| (3) any other neurological or mental health condition | ||
| for which ibogaine demonstrates efficacy. | ||
| (b) A consortium established under this section must | ||
| include one or more of each of the following entities: | ||
| (1) a drug developer; | ||
| (2) an institution of higher education; and | ||
| (3) a hospital. | ||
| Sec. 491.052. LEAD INSTITUTION; ADMINISTRATION; PERSONNEL. | ||
| (a) A consortium established under this subchapter shall select a | ||
| lead institution of higher education from among the consortium's | ||
| members to represent the consortium and perform administrative | ||
| functions under this subchapter, including contracting with and | ||
| reporting to the commission as required by this subchapter. | ||
| (b) A consortium selected by the commission under this | ||
| subchapter may employ personnel, including clinical, | ||
| administrative, and data management personnel, necessary to | ||
| support any consortium member's activities related to drug | ||
| development clinical trials conducted under this subchapter. | ||
| Sec. 491.053. CONSORTIUM PROPOSAL. (a) The lead | ||
| institution of higher education of a consortium shall submit to the | ||
| commission a proposal and request for funding on behalf of the | ||
| consortium for purposes of conducting ibogaine drug development | ||
| clinical trials in accordance with this subchapter. | ||
| (b) A proposal submitted under Subsection (a) must provide: | ||
| (1) the identity of all consortium members; | ||
| (2) a detailed description of the planned strategy for | ||
| obtaining approval for the drug development clinical trials from | ||
| the United States Food and Drug Administration; | ||
| (3) a detailed drug development clinical trial design | ||
| that includes: | ||
| (A) a description of the composition of the | ||
| consortium's drug development clinical trial team and the expertise | ||
| of the team members; | ||
| (B) a drug development clinical trial | ||
| participant recruitment plan; | ||
| (C) patient screening criteria and cardiac | ||
| safety protocols; | ||
| (D) administration protocols; | ||
| (E) an aftercare and post-acute treatment | ||
| support plan; and | ||
| (F) a data integrity plan; | ||
| (4) a detailed plan to seek a breakthrough therapy | ||
| designation for ibogaine from the United States Food and Drug | ||
| Administration under 21 U.S.C. Section 356; | ||
| (5) a proposal to recognize this state's commercial | ||
| interest in all intellectual property that may be generated over | ||
| the course of the drug development clinical trials, including: | ||
| (A) the treatment that is the subject of the | ||
| trials; | ||
| (B) administration protocols; | ||
| (C) treatment models or techniques; and | ||
| (D) technology used in the trials; | ||
| (6) a plan to establish a corporate presence in this | ||
| state and to promote and maintain ibogaine-related biomedical | ||
| research, development, treatment, manufacturing, and distribution | ||
| in this state; | ||
| (7) a plan to secure third-party payor approval for | ||
| ibogaine treatment following approval by the United States Food and | ||
| Drug Administration through: | ||
| (A) private insurers; | ||
| (B) Medicare; | ||
| (C) Medicaid; and | ||
| (D) the TRICARE program of the United States | ||
| Department of Defense; | ||
| (8) a plan to ensure ibogaine treatment access to | ||
| uninsured individuals following approval by the United States Food | ||
| and Drug Administration; | ||
| (9) a plan to train and credential medical providers | ||
| to administer ibogaine treatment according to developed clinical | ||
| standards; and | ||
| (10) financial disclosures that verify the | ||
| consortium's capacity to fully match state funding with funds | ||
| received from non-state sources. | ||
| Sec. 491.054. COMMISSION SELECTION. The commission, in the | ||
| commission's sole discretion, shall select a consortium | ||
| established in accordance with Section 491.051 for the purpose of | ||
| conducting ibogaine drug development clinical trials under this | ||
| subchapter. | ||
| Sec. 491.055. CONTRACT WITH LEAD INSTITUTION. (a) As soon | ||
| as practicable after selecting a consortium to conduct ibogaine | ||
| drug development clinical trials under Section 491.054, the | ||
| commission shall enter into an interagency contract, as provided by | ||
| Chapter 771, Government Code, with the lead institution of higher | ||
| education of the selected consortium to provide funding to | ||
| implement the consortium's proposed ibogaine drug development | ||
| clinical trials. | ||
| (b) The interagency contract described by Subsection (a) | ||
| must specify: | ||
| (1) the goals and objectives of the proposed ibogaine | ||
| drug development clinical trials; | ||
| (2) the proposed budget; | ||
| (3) the timeline for completing the proposed | ||
| objectives; | ||
| (4) the for-profit, nonprofit, or public benefit | ||
| corporate entities collaborating with the consortium in the drug | ||
| development clinical trials under this subchapter; | ||
| (5) the percentage of the revenue arising from the | ||
| drug development clinical trials to be paid to the state; and | ||
| (6) any other information required by the commission. | ||
| (c) As soon as practicable after entering into an | ||
| interagency contract under Subsection (a), the commission shall | ||
| report the existence of the contract to the legislature. | ||
| (d) The commission may not disburse funds to or for a | ||
| selected consortium under the interagency contract described by | ||
| Subsection (a) until the consortium receives and the commission | ||
| verifies the receipt of matching funds from sources other than the | ||
| state. | ||
| Sec. 491.056. INVESTIGATIONAL NEW DRUG APPLICATION. On the | ||
| commission's notification that a consortium is selected to conduct | ||
| the drug development clinical trials under this subchapter, a drug | ||
| developer or hospital member of the selected consortium or the lead | ||
| institution of higher education of the consortium, as specified by | ||
| written agreement of the consortium members, shall, as soon as | ||
| practicable: | ||
| (1) submit an investigational new drug (IND) | ||
| application to the United States Food and Drug Administration in | ||
| accordance with 21 C.F.R. Part 312; and | ||
| (2) seek a breakthrough therapy designation for | ||
| ibogaine from the United States Food and Drug Administration under | ||
| 21 U.S.C. Section 356. | ||
| Sec. 491.057. DRUG DEVELOPMENT CLINICAL TRIAL SITES. For | ||
| purposes of conducting a drug development clinical trial under this | ||
| subchapter, only an institution of higher education or a hospital | ||
| may serve as a trial site. | ||
| Sec. 491.058. FUNDING; DISBURSEMENT BY COMMISSION. (a) | ||
| The commission and consortium members may solicit and accept gifts, | ||
| grants, and donations of any kind received from sources other than | ||
| the state for purposes of funding drug development clinical trials | ||
| under this subchapter. | ||
| (b) Disbursements of funds by the commission may be made | ||
| incrementally based on the completion of clearly defined objectives | ||
| as negotiated in the contract described by Section 491.055, | ||
| including verifiable documentation demonstrating the efficient | ||
| expenditure of both state and matching funds. | ||
| Sec. 491.059. REPORTING REQUIREMENTS. (a) A consortium | ||
| selected to conduct ibogaine drug development clinical trials shall | ||
| quarterly prepare and submit to the commission: | ||
| (1) a report on the progress of the drug development | ||
| clinical trials conducted under this subchapter; and | ||
| (2) a financial status report, including information | ||
| to verify expenditures of state funds and required matching funds. | ||
| (b) The commission shall submit a report to the legislature | ||
| on the progress of the drug development clinical trials conducted | ||
| under this subchapter not later than December 1 of each year. | ||
| Sec. 491.060. ALLOCATION OF REVENUE ATTRIBUTABLE TO | ||
| INTELLECTUAL PROPERTY AND OTHER RIGHTS. (a) The revenue | ||
| attributable to all intellectual property rights and other | ||
| commercial rights arising from drug development clinical trials | ||
| conducted by a consortium under this subchapter during the period | ||
| for which the trials are funded and any following period of | ||
| commercialization shall be allocated as follows: | ||
| (1) not less than 20 percent to the state as specified | ||
| in the contract under Section 491.055; and | ||
| (2) the remainder to the members of the consortium in | ||
| the amounts specified by written agreement of the members. | ||
| (b) For purposes of this section, intellectual property | ||
| rights and other commercial rights arising from the drug | ||
| development clinical trials conducted under this subchapter | ||
| include any of the following as related to the trials: | ||
| (1) intellectual property, technology, and | ||
| inventions; | ||
| (2) patents, trademarks, and licenses; | ||
| (3) proprietary and confidential information; | ||
| (4) trade secrets, data, and databases; | ||
| (5) tools, methods, and processes; | ||
| (6) treatment models or techniques; | ||
| (7) administration protocols; and | ||
| (8) works of authorship. | ||
| Sec. 491.061. USE OF STATE REVENUE. (a) The comptroller | ||
| shall deposit the revenue received under Section 491.060 to the | ||
| credit of the general revenue fund. | ||
| (b) Of the amount deposited under Subsection (a), 25 percent | ||
| may be appropriated only to programs that assist veterans in this | ||
| state. | ||
| (c) The comptroller shall develop accounting procedures for | ||
| the purpose of implementing this section. | ||
| SUBCHAPTER C. IBOGAINE TREATMENT ADMINISTRATION | ||
| Sec. 491.101. APPLICABILITY. This subchapter applies only | ||
| if ibogaine is approved by the United States Food and Drug | ||
| Administration to treat a medical condition. | ||
| Sec. 491.102. MEDICAL SUPERVISION. A physician licensed | ||
| under Subtitle B, Title 3, Occupations Code, who has prescribed | ||
| ibogaine for a patient shall supervise the administration of | ||
| ibogaine at a hospital or other licensed health care facility to | ||
| ensure the patient's safety while the patient is under the | ||
| influence of ibogaine. | ||
| Sec. 491.103. ADMINISTRATION UNDER FEDERAL LAW. This | ||
| subchapter does not preclude a physician from administering | ||
| ibogaine in accordance with federal law. | ||
| SECTION 2. (a) If before implementing any provision of this | ||
| Act a state agency determines that a waiver or authorization from a | ||
| federal agency is necessary for implementation of that provision, | ||
| the agency affected by the provision shall request the waiver or | ||
| authorization and may delay implementing that provision until the | ||
| waiver or authorization is granted. | ||
| (b) The Health and Human Services Commission shall begin | ||
| accepting proposals from consortiums under Chapter 491, Health and | ||
| Safety Code, as added by this Act, not later than the 60th day after | ||
| the effective date of this Act. | ||
| SECTION 3. This Act takes effect immediately if it receives | ||
| a vote of two-thirds of all the members elected to each house, as | ||
| provided by Section 39, Article III, Texas Constitution. If this | ||
| Act does not receive the vote necessary for immediate effect, this | ||
| Act takes effect September 1, 2025. | ||
| ______________________________ | ______________________________ | |
| President of the Senate | Speaker of the House | |
| I hereby certify that S.B. No. 2308 passed the Senate on | ||
| April 30, 2025, by the following vote: Yeas 26, Nays 5; | ||
| May 15, 2025, Senate refused to concur in House amendments and | ||
| requested appointment of Conference Committee; May 20, 2025, House | ||
| granted request of the Senate; May 31, 2025, Senate adopted | ||
| Conference Committee Report by the following vote: Yeas 27, | ||
| Nays 4. | ||
| ______________________________ | ||
| Secretary of the Senate | ||
| I hereby certify that S.B. No. 2308 passed the House, with | ||
| amendments, on May 13, 2025, by the following vote: Yeas 138, | ||
| Nays 2, two present not voting; May 20, 2025, House granted request | ||
| of the Senate for appointment of Conference Committee; | ||
| June 1, 2025, House adopted Conference Committee Report by the | ||
| following vote: Yeas 134, Nays 4, one present not voting. | ||
| ______________________________ | ||
| Chief Clerk of the House | ||
| Approved: | ||
| ______________________________ | ||
| Date | ||
| ______________________________ | ||
| Governor |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.